Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 25 of 2051 entries
View as:

MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)

Phase: N/A Priority: Normal
NCT ID: NCT00099346 Org: User:
Start: 01/31/05 End: 04/30/07 Due: 04/30/08

A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)

Phase: N/A Priority: Normal
NCT ID: NCT04317066 Org: User:
Start: 06/26/20 End: 04/11/24 Due: 04/11/25

A Study of MK0657 in Parkinson's Disease Patients (0657-006)

Phase: N/A Priority: Normal
NCT ID: NCT00505843 Org: User:
Start: 05/31/07 End: 02/29/08 Due: 02/28/09

A Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years (0633-019)

Phase: N/A Priority: Normal
NCT ID: NCT00646789 Org: User:
Start: 05/31/08 End: 07/31/08 Due: 07/31/09

MSD Belzutifan PAS

Phase: N/A Priority: Normal
NCT ID: NCT06554730 Org: User:
Start: 06/30/24 End: 12/31/30 Due: 12/31/31

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

Phase: N/A Priority: Normal
NCT ID: NCT03564691 Org: User:
Start: 07/11/18 End: 09/28/25 Due: 09/28/26

MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)

Phase: N/A Priority: Normal
NCT ID: NCT03552536 Org: User:
Start: 10/07/18 End: 03/11/19 Due: 03/11/20

Single-Ascending Dose Study of MK-2060 in Healthy Chinese Male Adult Participants (MK-2060-009)

Phase: N/A Priority: Normal
NCT ID: NCT06843993 Org: User:
Start: 03/01/23 End: 10/27/23 Due: 10/27/24

Effect of Vicriviroc on HIV Ribonucleic Acid (RNA) Levels in Cerebrospinal Fluid (Study P05241)

Phase: N/A Priority: Normal
NCT ID: NCT00632073 Org: User:
Start: 03/31/08 End: 03/31/10 Due: 03/31/11

Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101)

Phase: N/A Priority: Normal
NCT ID: NCT01050543 Org: User:
Start: 02/01/10 End: 08/20/10 Due: 08/20/11

A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)

Phase: N/A Priority: Normal
NCT ID: NCT01527383 Org: User:
Start: 02/21/12 End: 02/26/13 Due: 02/26/14

A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)

Phase: N/A Priority: Normal
NCT ID: NCT01293643 Org: User:
Start: 05/31/10 End: 01/31/11 Due: 01/31/12

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

Phase: N/A Priority: Normal
NCT ID: NCT04740307 Org: User:
Start: 03/16/21 End: 03/08/26 Due: 03/08/27

Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)

Phase: N/A Priority: Normal
NCT ID: NCT00725205 Org: User:
Start: 03/31/06 End: 10/31/10 Due: 10/31/11

Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)

Phase: N/A Priority: Normal
NCT ID: NCT00773838 Org: User:
Start: 12/01/08 End: 04/09/12 Due: 04/09/13

A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)

Phase: N/A Priority: Normal
NCT ID: NCT02549027 Org: User:
Start: 11/06/09 End: 04/06/10 Due: 04/06/11

A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)

Phase: N/A Priority: Normal
NCT ID: NCT05038800 Org: User:
Start: 09/26/21 End: 12/11/23 Due: 12/11/24

A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED)

Phase: N/A Priority: Normal
NCT ID: NCT00758680 Org: User:
Start: 08/31/08 End: 03/31/10 Due: 03/31/11

Januvia Re-examination Study (MK-0431-181)

Phase: N/A Priority: Normal
NCT ID: NCT01062048 Org: User:
Start: 10/31/08 End: 07/31/13 Due: 07/31/14

Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)

Phase: N/A Priority: Normal
NCT ID: NCT01215175 Org: User:
Start: 09/25/09 End: 01/05/11 Due: 01/05/12

Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)

Phase: N/A Priority: Normal
NCT ID: NCT00863109 Org: User:
Start: 04/30/09 End: 05/31/13 Due: 05/31/14

The Effects of Diquafosol Tetrasodium Ophthalmic Solution, 2% in Subjects With Dry Eye Disease (P08637)

Phase: N/A Priority: Normal
NCT ID: NCT00831662 Org: User:
Start: 01/31/09 End: 12/31/09 Due: 12/31/10

2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00090155 Org: User:
Start: 09/26/03 End: 11/24/04 Due: 11/24/05

MK-0524B Lipid Study (MK-0524B-063)

Phase: N/A Priority: Normal
NCT ID: NCT00479882 Org: User:
Start: 06/15/07 End: 06/16/08 Due: 06/16/09

GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)

Phase: N/A Priority: Normal
NCT ID: NCT00546624 Org: User:
Start: 11/30/02 End: 02/28/03 Due: 02/28/04